Analyzing the Market Forecast for HCA Stock

This afternoon we watched HCA Healthcare drop -2.4% to a price of $306.69 per share. The Large-Cap Medical Care Facility company is now trading -9.78% below its average target price of $339.94. Analysts have set target prices ranging from $250.0 to $378.0 per share for HCA Healthcare, and have given the stock an average rating of buy.

The stock has a very low short interest at 1.4%, and a short ratio of 3.11. The company's insiders own 27.22% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 64.9% of HCA Healthcare's shares being owned by this investor type.

Institutions Invested in HCA Healthcare

Date Reported Holder Percentage Shares Value
2023-12-31 Vanguard Group Inc 6% 16,929,379 $5,192,071,286
2023-12-31 Blackrock Inc. 5% 14,531,079 $4,456,536,653
2023-12-31 Sanders Capital, LLC 4% 11,404,003 $3,497,493,707
2023-12-31 Wellington Management Group, LLP 4% 10,186,129 $3,123,983,927
2023-12-31 State Street Corporation 3% 8,570,184 $2,628,389,751
2023-12-31 First Eagle Investment Management, LLC 2% 4,501,815 $1,380,661,653
2023-12-31 Royal Bank of Canada 2% 4,503,918 $1,381,306,622
2023-12-31 Geode Capital Management, LLC 1% 3,799,842 $1,165,373,552
2023-12-31 Bank of America Corporation 1% 3,342,615 $1,025,146,602
2023-12-31 Price (T.Rowe) Associates Inc 1% 3,315,465 $1,016,819,968

Besides an analyst consensus of some upside potential, other market factors point to there being positive market sentiment on HCA Healthcare.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.